ConductScience.org, home

Comparison · NCT00514709-sae

Group 1: DTaP-Hep B-PRP~T + OPV vs Group 2: Tritanrix-Hep B/ Hib™ + OPV: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Group 1: DTaP-Hep B-PRP~T + OPV vs Group 2: Tritanrix-Hep B/ Hib™ + OPV: serious adverse events. Trial comparisons, record NCT00514709-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00514709-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.002440.000830.00715wilson
Risk in group 200.0000000000000000004340.00623wilson
Risk difference, group 1 minus group 20.00244-0.003990.00715newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more participant with a serious adverse event on Group 1: DTaP-Hep B-PRP~T + OPV than on Group 2: Tritanrix-Hep B/ Hib™ + OPV410from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Group 1: DTaP-Hep B-PRP~T + OPV
Participants received a booster dose of the DTaP-Hep B-PRP\~T Combined vaccine concomitantly with oral polio vaccine (OPV) following a 3-dose primary series of DTaP-Hep B-PRP\~T combined vaccine concomitantly with OPV at 6, 10, and 14 weeks of age in Study AL201.
31,230EG000
Group 2Group 2: Tritanrix-Hep B/ Hib™ + OPV
Participants received a booster dose of the DTaP-Hep B-PRP\~T Combined vaccine concomitantly with oral polio vaccine (OPV) following a 3-dose primary series of Tritanrix-Hep B/Hib™ concomitantly with OPV at 6, 10, and 14 weeks of age in Study AL201.
0613EG001

Harm

What it counts
Total, serious adverse events
Time frame
Adverse event data were collected from Day 0 (post-vaccination) up to Day 30 post-vaccination.

Source ClinicalTrials.gov

Trial

Title
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
NCT number
NCT00514709
Phases
PHASE3
Conditions
Diphtheria, Tetanus, Pertussis, Hepatitis B, Influenza
Interventions
DTaP-HB PRP~T Combined Vaccine, DTaP-HB-PRP~T vaccine, Oral Polio Vaccine
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Results first posted
2013-11-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00514709-sae